TRxADE HEALTH Inc. (MEDS)
NASDAQ: MEDS
· Real-Time Price · USD
7.59
0.33 (4.55%)
At close: Sep 20, 2024, 10:00 PM
TRxADE HEALTH Revenue Breakdown
| Period Ending | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|
| Other Segments Revenue | 19.2K | 82.91K | 62.02K |
| Other Segments Revenue Growth | -76.84% | +33.69% | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2024 |
|---|---|
| United States Revenue | 136.64K |
| United States Revenue Growth | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 1.77M | 850.79K | 2.09M | 1.41M | 5.49M | 3.58M | 2.14M | 1.55M | 1.67M | 1.5M | 1.51M | 1.98M | 2.06M | 2.02M | 2.58M | 2.19M | 2.03M | 1.71M | 1.78M | 2.54M | 1.31M | 1.24M | 1.13M | 1.03M | 938.94K | 36.84K | 753.3K | 806.24K | 754.2K | 361.66K | 646.25K | 655.95K | 604.49K | -718.28K | 1.36M | 1.66M | 1.14M | 1.32M | 1.01M | 811.64K | 908.32K |
| Selling, General, and Administrative Revenue Growth | +107.90% | -59.30% | +48.42% | -74.34% | +53.40% | +67.25% | +38.10% | -7.31% | +11.26% | -0.56% | -23.56% | -4.01% | +1.78% | -21.48% | +17.84% | +7.81% | +18.39% | -3.98% | -29.79% | +93.78% | +5.81% | +9.38% | +9.91% | +9.76% | +2449.05% | -95.11% | -6.57% | +6.90% | +108.54% | -44.04% | -1.48% | +8.51% | -184.16% | -152.64% | -17.92% | +45.73% | -13.41% | +29.95% | +24.91% | -10.64% | n/a |
| Research and Development Revenue | 574.68K | 928.85K | 1.25M | n/a | 53.86K | 366.53K | 410.61K | 441.38K | 233.29K | 318.42K | 298.59K | 298.06K | 245.78K | 1.37M | n/a | n/a | n/a | 662.73K | n/a | n/a | n/a | 647.14K | n/a | n/a | n/a | 949.95K | n/a | n/a | n/a | 863.32K | n/a | n/a | n/a | 286.76K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Research and Development Revenue Growth | -38.13% | -25.93% | n/a | -100.00% | -85.31% | -10.73% | -6.97% | +89.20% | -26.74% | +6.64% | +0.18% | +21.27% | -82.03% | n/a | n/a | n/a | -100.00% | n/a | n/a | n/a | -100.00% | n/a | n/a | n/a | -100.00% | n/a | n/a | n/a | -100.00% | n/a | n/a | n/a | -100.00% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |